ATE458747T1 - Angiontensin converting enzyme hemmendes peptid - Google Patents

Angiontensin converting enzyme hemmendes peptid

Info

Publication number: ATE458747T1
Authority: AT; Austria
Prior art keywords: converting enzyme; inhibiting peptide; enzyme inhibiting; angiontensin; peptide
Prior art date: 2003-12-01

Application number

AT04801616T

Other languages

English (en)

Inventor

Hidekazu Tonouchi

Masayuki Suzuki

Masayuki Uchida

Munehiro Oda

Original Assignee

Meiji Dairies Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-01

Filing date

2004-12-01

Publication date

2010-03-15

2004-12-01 Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE458747T1 publication Critical patent/ATE458747T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
230000002401 inhibitory effect Effects 0.000 title abstract 2
102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT04801616T 2003-12-01 2004-12-01 Angiontensin converting enzyme hemmendes peptid ATE458747T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003401405		2003-12-01
PCT/JP2004/018235 WO2005061529A1 (ja)	2003-12-01	2004-12-01	アンジオテンシン変換酵素阻害ペプチド

Publications (1)

Publication Number	Publication Date
ATE458747T1 true ATE458747T1 (de)	2010-03-15

Family

ID=34708657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04801616T ATE458747T1 (de)	2003-12-01	2004-12-01	Angiontensin converting enzyme hemmendes peptid

Country Status (11)

Country	Link
US (1)	US8637463B2 (de)
EP (1)	EP1690869B1 (de)
JP (1)	JP4628958B2 (de)
KR (1)	KR101176673B1 (de)
CN (3)	CN102030818B (de)
AT (1)	ATE458747T1 (de)
AU (1)	AU2004303647B2 (de)
CA (1)	CA2549185C (de)
DE (1)	DE602004025730D1 (de)
NZ (3)	NZ587702A (de)
WO (1)	WO2005061529A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006239560B2 (en) *	2005-04-28	2010-03-25	Unilever Plc	Peptides having an ace inhibiting effect
CA2603237A1 (en) *	2005-04-28	2006-11-02	Dsm Ip Assets B.V.	Novel nutraceutical compositions
WO2006114194A1 (en) *	2005-04-28	2006-11-02	Unilever N.V.	Peptides having a health benefit and compositions comprising them
US20090304869A1 (en) *	2005-04-28	2009-12-10	Christianus Jacobus Van Platerink	Peptides Having an Ace Inhibiting Effect
EP1881841A1 (de) *	2005-04-28	2008-01-30	Unilever N.V.	Zusammensetzungen mit ace hemmenden tripeptiden
JP2008208096A (ja) *	2007-02-28	2008-09-11	Kanetoku:Kk	クラゲタンパク質由来の新規ペプチドとその用途
ES2324192B1 (es) *	2008-01-30	2010-06-17	PUIG BEAUTY & FASHION GROUP, S.L.	Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
CN104592350A (zh) *	2013-06-18	2015-05-06	天津商业大学	一种ace抑制肽及其制备方法
FR3017536B1 (fr) *	2014-02-18	2017-05-26	Univ La Rochelle	Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
CN104356209A (zh) *	2014-08-28	2015-02-18	中国人民解放军第四军医大学	一种降低血压以及保护心脏的多肽
CN109734776B (zh) *	2018-10-23	2020-10-20	渤海大学	一种具有ace抑制活性和dpp-iv抑制活性的三肽
CN113321719B (zh) *	2021-05-20	2022-03-18	澳优乳业（中国）有限公司	一种寡肽及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4216209A (en)	1979-03-19	1980-08-05	American Home Products Corporation	Tripeptide angiotensin converting enzyme inhibitors
GB9225021D0 (en) *	1992-11-30	1993-01-20	Sandoz Ltd	Organic compounds
JP3465922B2 (ja) *	1993-03-26	2003-11-10	日本合成化学工業株式会社	新規ペプチド、それを製造する方法及び用途
JP3465921B2 (ja) *	1993-03-26	2003-11-10	日本合成化学工業株式会社	新規ペプチド、それを製造する方法及び用途
JP3465923B2 (ja) *	1993-03-26	2003-11-10	日本合成化学工業株式会社	新規ペプチド、それを製造する方法及び用途
JP3483212B2 (ja) *	1993-10-06	2004-01-06	日本合成化学工業株式会社	新規ペプチド、それを製造する方法及び用途
GB9616351D0 (en) *	1996-08-02	1996-09-11	Smithkline Beecham Biolog	Vaccine composition
US6207391B1 (en) *	1998-03-31	2001-03-27	Tularik Inc.	High-throughput screening assays for modulators of STAT4 and STAT6 activity
US6261794B1 (en) *	1999-10-14	2001-07-17	Saint Louis University	Methods for identifying inhibitors of methionine aminopeptidases
JP2002121199A (ja) *	2000-10-13	2002-04-23	Shimaya Co Ltd	新規ペプチドおよびその製造方法
JP2002138100A (ja) *	2000-10-27	2002-05-14	Riken Vitamin Co Ltd	アンジオテンシン変換酵素阻害物質
JP2003051163A (ja) *	2001-05-28	2003-02-21	Sharp Corp	信号品質評価方法及び再生装置
US6900033B2 (en) *	2001-06-04	2005-05-31	Human Genome Sciences, Inc.	Methods and compositions for modulating ACE-2 activity
CA2468039C (en) *	2001-11-21	2011-01-04	Morinaga Milk Industry Co., Ltd.	Novel peptide having angiotensin converting enzyme inhibitory effect
DE10225144A1 (de) *	2002-05-29	2003-12-18	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide

2004
- 2004-12-01 AT AT04801616T patent/ATE458747T1/de not_active IP Right Cessation
- 2004-12-01 NZ NZ587702A patent/NZ587702A/en not_active IP Right Cessation
- 2004-12-01 WO PCT/JP2004/018235 patent/WO2005061529A1/ja not_active Ceased
- 2004-12-01 NZ NZ584979A patent/NZ584979A/en not_active IP Right Cessation
- 2004-12-01 KR KR1020067013202A patent/KR101176673B1/ko not_active Expired - Fee Related
- 2004-12-01 US US10/581,304 patent/US8637463B2/en not_active Expired - Fee Related
- 2004-12-01 CN CN2010105474769A patent/CN102030818B/zh not_active Expired - Fee Related
- 2004-12-01 JP JP2005516450A patent/JP4628958B2/ja not_active Expired - Lifetime
- 2004-12-01 CN CN2010105474608A patent/CN102030817B/zh not_active Expired - Fee Related
- 2004-12-01 AU AU2004303647A patent/AU2004303647B2/en not_active Ceased
- 2004-12-01 DE DE602004025730T patent/DE602004025730D1/de not_active Expired - Lifetime
- 2004-12-01 EP EP04801616A patent/EP1690869B1/de not_active Expired - Lifetime
- 2004-12-01 CA CA2549185A patent/CA2549185C/en not_active Expired - Lifetime
- 2004-12-01 CN CN2004800356650A patent/CN1894273B/zh not_active Expired - Fee Related
- 2004-12-01 NZ NZ548166A patent/NZ548166A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN102030818B (zh)	2013-03-27
NZ548166A (en)	2010-06-25
CN102030817A (zh)	2011-04-27
US8637463B2 (en)	2014-01-28
EP1690869A1 (de)	2006-08-16
CN102030818A (zh)	2011-04-27
AU2004303647A1 (en)	2005-07-07
NZ587702A (en)	2011-06-30
CA2549185C (en)	2012-10-30
EP1690869A4 (de)	2007-02-28
WO2005061529A1 (ja)	2005-07-07
JPWO2005061529A1 (ja)	2007-12-20
AU2004303647B2 (en)	2010-05-27
NZ584979A (en)	2010-10-29
KR20060128899A (ko)	2006-12-14
CN1894273B (zh)	2011-01-12
KR101176673B1 (ko)	2012-08-23
CN102030817B (zh)	2012-11-21
JP4628958B2 (ja)	2011-02-09
CN1894273A (zh)	2007-01-10
CA2549185A1 (en)	2005-07-07
US20090163425A1 (en)	2009-06-25
DE602004025730D1 (en)	2010-04-08
EP1690869B1 (de)	2010-02-24

Legal Events

Date	Code	Title	Description
2010-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
YU9404A (sh)	2006-08-17	Multimerna, usmerena kontrastna sredstva na bazi peptida
BR9908280A (pt)	2000-10-31	Inibidores de enzimas de fosfolipase
DE60007095T2 (de)	2004-10-07	Calanolide zur hemmung von btk
IL151313A0 (en)	2003-04-10	Lipase containing pharmaceutical compositions
PL1938832T3 (pl)	2013-06-28	Peptydy jako czynniki hamujące enzym przekształcający angiotensynę
SG158141A1 (en)	2010-01-29	Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DE602004025730D1 (en)	2010-04-08	Angiontensin converting enzyme hemmendes peptid
WO2004009616A3 (en)	2006-02-09	Ghrelin analogs
AP2004003154A0 (en)	2004-12-31	Novel perindopril salt and pharmaceutical compositions containing same.
WO2003010291A3 (en)	2004-02-19	Treatment of immune disorders and b cell disorders
PL1622939T3 (pl)	2012-08-31	Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
MXPA05011783A (es)	2006-01-26	Peptidos que tienen un efecto inhibidor de enzima convertidora de angiotensina.
WO2003092631A3 (en)	2005-04-28	Cyclic peptide anti-viral agents and methods
WO2004019965A3 (en)	2004-04-22	Thymus-based tolerogenic approaches for type i diabetes.
HUP0400262A2 (hu)	2004-08-30	Glikopeptidek, előállításuk és alkalmazásuk szklerózis multiplex kezelésében
IL173929A0 (en)	2006-07-05	Analogues of kahalalide f and pharmaceutical compositions containing the same
DE60041198D1 (de)	2009-02-05	Antimikrobielle zusammensetzungen
WO2002093127A3 (en)	2004-09-23	Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
ZA200403602B (en)	2005-08-31	Oligopeptides and compositions containing them as cathepsin S inhibitors.
SI1539815T1 (sl)	2009-06-30	Kristalna struktura encima, ki pretvarja angiotenzin (ACE), in njegove uporabe
DE60333351D1 (de)	2010-08-26	N-substituiertes benzothiophensulfonamidderivat
DE602004022453D1 (de)	2009-09-17	Peptide mit ace-hemmwirkung
WO2004020466A8 (en)	2005-01-20	Protein tyrosine phosphatase inhibitors
WO2004052918A3 (en)	2005-06-02	Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides
WO2004016737A3 (en)	2006-01-05	Novel htnfsf13b protein variants